HK1067073A1 - Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation - Google Patents

Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Info

Publication number
HK1067073A1
HK1067073A1 HK05100604.3A HK05100604A HK1067073A1 HK 1067073 A1 HK1067073 A1 HK 1067073A1 HK 05100604 A HK05100604 A HK 05100604A HK 1067073 A1 HK1067073 A1 HK 1067073A1
Authority
HK
Hong Kong
Prior art keywords
gram positive
treatment
positive bacteria
diseases
immune dysregulation
Prior art date
Application number
HK05100604.3A
Other languages
English (en)
Inventor
Marie-Anne Nahori
Micheline Lagranderie
Gilles Marchal
Bernardo Boris Vargaftig
Jean Lefort
Felix Romain
Georges Hekimian
Philippe Peltre
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Publication of HK1067073A1 publication Critical patent/HK1067073A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
HK05100604.3A 2001-12-11 2005-01-21 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation HK1067073A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403195 2001-12-11
PCT/IB2002/005760 WO2003049752A2 (fr) 2001-12-11 2002-12-11 Preparations a base de bacteries gram positif destinees au traitement de maladies presentant un dysfonctionnement immunitaire

Publications (1)

Publication Number Publication Date
HK1067073A1 true HK1067073A1 (en) 2005-04-01

Family

ID=8183013

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100604.3A HK1067073A1 (en) 2001-12-11 2005-01-21 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Country Status (18)

Country Link
US (3) US20060062807A1 (fr)
EP (2) EP2316466B1 (fr)
JP (2) JP4737586B2 (fr)
KR (2) KR101124363B1 (fr)
CN (1) CN1602199B (fr)
AT (1) ATE466585T1 (fr)
AU (1) AU2002356387C1 (fr)
BR (1) BR0214902A (fr)
CA (1) CA2469334C (fr)
CY (1) CY1110727T1 (fr)
DE (1) DE60236318D1 (fr)
DK (2) DK2316466T3 (fr)
ES (1) ES2345188T3 (fr)
HK (1) HK1067073A1 (fr)
NZ (2) NZ555055A (fr)
PT (1) PT1461054E (fr)
SI (1) SI1461054T1 (fr)
WO (1) WO2003049752A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214902A (pt) * 2001-12-11 2004-11-30 Pasteur Institut Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos
ES2471241T3 (es) * 2002-09-06 2014-06-25 Ucl Business Plc Células bacterianas completas como inmunomodulador
ES2347566T3 (es) 2003-11-14 2010-11-02 Ucl Business Plc Inmunomodulador que comprende celulas enteras de bacterias tsukamurella.
WO2005080414A1 (fr) 2004-02-19 2005-09-01 Ramot At Tel-Aviv University Ltd Mimotopes peptidiques des lipoglycanes mannosyles mycobacteriens et utilisation de ces mimotopes
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
ES2404695T3 (es) * 2004-06-07 2013-05-28 Qu Biologics Inc Composiciones bacterianas para el tratamiento del cáncer
EP1761631B1 (fr) 2004-06-24 2009-10-28 Yissum Research Development Company Utilisation de mimotopes peptidiques de lipoglycanes mannosylates mycobacteriens pour traiter une inflammation
CA2531261A1 (fr) * 2005-12-21 2007-06-21 Institut Pasteur Traitement de syndromes d'inflammation intestinale a l'aide d'une preparation a base de bacteries tuees ou non infectieuses
NZ576590A (en) * 2006-10-27 2012-08-31 Qu Biolog Inc Tissue targeted antigenic activation of the immune response to treat cancers
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
EP2087898A1 (fr) * 2008-02-06 2009-08-12 Institut Pasteur Préparation de BCG de Mycobacterium bovis tué par lyophilisation étendue pour traiter l'arthrite rhumatoïde
CA2629057A1 (fr) * 2008-04-14 2009-10-14 Institut Pasteur Controle de maladies associees a une diminution des cellules t suppressives au moyen d'une preparation de bacteries mortes lyophilisees etendue
HUP0900231A2 (hu) * 2009-04-16 2010-11-29 Hyd Rakkutato Es Gyogyszerfejlesztoe Kft Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására
EP2292260A1 (fr) 2009-08-13 2011-03-09 Institut Pasteur Utilisation de mycobactérie bois tuée par lyophilisation étendue pour la prévention ou le traitement de l'athérosclérose
EP2620159A1 (fr) 2012-01-24 2013-07-31 Institut Pasteur Traitement du cancer amélioré par immunothérapie par BCG ou des mycobactéries non pathogènes apparentées du point de vue des antigènes
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
CA3015688A1 (fr) * 2016-02-25 2017-08-31 Thomas Julius Borody Compositions et procedes de traitement de maladies infectieuses chroniques
US20210353693A1 (en) * 2018-10-17 2021-11-18 SciBac Inc. Live Biotherapeutics to Treat and Prevent Lung Conditions
US20220047648A1 (en) * 2019-01-09 2022-02-17 Md Healthcare Inc. Nanovesicles derived from bacteria of genus rhodococcus, and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594471A (en) * 1946-10-11 1952-04-29 Comb Eng Superheater Inc Heat exchange apparatus
GB764718A (en) * 1954-08-10 1957-01-02 Glaxo Lab Ltd Improvements in or relating to freeze-drying processes
GB1027979A (en) * 1963-07-12 1966-05-04 Ciba Ltd Process for obtaining bcg-cultures
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
JPS57186495A (en) 1981-05-14 1982-11-16 Ube Ind Ltd Preparation of l-alpha-methylphenylalanine
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
NZ216119A (en) 1985-05-13 1989-01-06 Commw Scient Ind Res Org Vaccine produced using antigens of a pseudocapsule producing strain of s.aureus
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPS63126830A (ja) * 1986-11-17 1988-05-30 Isao Moriya 動植物の体内に抗体を生成する方法
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
BR0214902A (pt) 2001-12-11 2004-11-30 Pasteur Institut Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos

Also Published As

Publication number Publication date
BR0214902A (pt) 2004-11-30
ATE466585T1 (de) 2010-05-15
KR20110028558A (ko) 2011-03-18
PT1461054E (pt) 2010-08-09
AU2002356387B2 (en) 2007-09-13
CN1602199B (zh) 2012-04-04
AU2002356387C1 (en) 2008-03-06
AU2002356387A1 (en) 2003-06-23
EP2316466A2 (fr) 2011-05-04
JP4737586B2 (ja) 2011-08-03
WO2003049752A3 (fr) 2003-11-20
CN1602199A (zh) 2005-03-30
JP5417354B2 (ja) 2014-02-12
US20060062807A1 (en) 2006-03-23
EP2316466B1 (fr) 2013-08-21
KR101124363B1 (ko) 2012-03-21
DK2316466T3 (da) 2013-11-18
CA2469334A1 (fr) 2003-06-19
KR101048798B1 (ko) 2011-07-15
EP1461054A2 (fr) 2004-09-29
NZ533422A (en) 2008-03-28
US7871627B2 (en) 2011-01-18
US20070190076A1 (en) 2007-08-16
US8404250B2 (en) 2013-03-26
EP1461054B1 (fr) 2010-05-05
US20100272756A1 (en) 2010-10-28
JP2005516915A (ja) 2005-06-09
WO2003049752A2 (fr) 2003-06-19
JP2011121977A (ja) 2011-06-23
NZ555055A (en) 2010-06-25
SI1461054T1 (sl) 2010-09-30
KR20040080434A (ko) 2004-09-18
CA2469334C (fr) 2012-05-08
EP2316466A3 (fr) 2012-04-11
DK1461054T3 (da) 2010-08-16
ES2345188T3 (es) 2010-09-17
DE60236318D1 (de) 2010-06-17
CY1110727T1 (el) 2015-06-10

Similar Documents

Publication Publication Date Title
HK1067073A1 (en) Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
WO2001090129A3 (fr) Traitement prophylactique et therapeutique de maladies infectieuses et autres avec des composes a base de mono- et disaccharides
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
WO2004069156A3 (fr) Bacteries probiotiques inactivees et leurs procedes d'utilisation
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
EP1783126A3 (fr) N-oxydes de derives de N-phenyl-2-pyrimidine-amine
WO2002085299A3 (fr) Traitements therapeutiques recourant a l'application directe de compositions metalliques antimicrobiennes
WO2003099110A3 (fr) Herbes et combinaisons d'herbes utiles dans le traitement d'infections microbiennes
WO2003099771A3 (fr) Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
EP1262177A3 (fr) Utilisation médicale des composés thyromimétiques pour traiter la chute des cheveux et compositions
AU4073901A (en) Novel pharmaceutical or dietetic mushroom-based compositions
WO2004031129A3 (fr) Nouveaux composes destines au traitement des maladies auto-immunes, des maladies immuno-allergiques et des rejets en cas de greffes d'organes ou de tissus
WO2006004588A3 (fr) Complexes d'interaction immunitaire dynamique et procedes pour l'utilisation et la preparation de tels complexes
WO2002078742A3 (fr) Procedes et compositions destines au traitement de dysfonctions immunitaires
WO2002078741A3 (fr) Procedes et compositions destines a moduler le systeme immunitaire des animaux
WO2003063725A3 (fr) Procedes pour prevenir et traiter une infection a flavivirus chez des animaux
WO2005094790A8 (fr) Formulations liposomales
DE60235418D1 (de) Osteoprotegerin in Milch
EP1303300A4 (fr) Compositions et procedes de traitement de la candidiase
WO2003013440A3 (fr) Traitement et prevention de maladies et de conditions associees a la proteine de choc thermique
EP1472273A4 (fr) Compositions et methodes de traitement de maladies d'origine immune
WO2003024996A3 (fr) Macrocycles antibacteriens
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
WO2001095937A3 (fr) Compositions d'isoflavone phyto-oestrogeniques, leur preparation et leur utilisation a des fins de protection contre des lesions produites par rayonnement et de traitement de ces lesions

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161211